Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.

Biotechnology

Cue Biopharma

Dan Passeri

Siddhartha Shrivastava

Andrey Antov

Matteo Levisetti

Steven Quayle

Peter Sheridan

Natasha Girgis

James Murray

Colin Sandercock

Kerri-Ann Millar

Anish Suri

The Research and Development Team at Cue Biopharma is focused on advancing the company's immunotherapy therapies by conducting cutting-edge research on biologics designed to modulate the immune system. This team, composed of scientists and leaders across pharmacology, translational medicine, and toxicology, collaborates to design, test, and refine novel therapies that target disease-associated T cells, ultimately aiming to bring innovative treatment solutions for cancers and autoimmune disorders from the lab to clinical application.

Research and Development Team

Legal and Regulatory Affairs

Advisory Team

Research and Development Team

About

Team members

Other teams at Cue Biopharma

Legal and Regulatory Affairs

Advisory Team